July 01, 2020
Strongbridge Biopharma plc Announces Last Patient Completes Last Study Visit in the Randomized Withdrawal Phase of the LOGICS Trial Evaluating RECORLEV® (levoketoconazole) for Endogenous Cushing’s Syndrome
Media
June 30, 2020
Oncopeptides announces leadership changes: Jakob Lindberg assumes a new role as CSO, and Marty J Duvall is appointed CEO
June 30, 2020
Positive results from human PK study assessing Orexo’s intranasal nalmefene formulations for opioid overdose reversal
June 30, 2020
Oncopeptides submits a New Drug Application to the FDA for accelerated approval of melflufen in triple-class refractory multiple myeloma patients
June 30, 2020
Nordic Nanovector to amend PARADIGME trial protocol to expand eligible patient population
June 29, 2020
Oncopeptides strengthens the pre-clinical development and takes over Kancera´s Solna-based laboratory for drug development as of July 1
June 29, 2020
Aprea Therapeutics Appoints Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to Board of Directors
June 29, 2020
Nordic Nanovector’s Betalutin® Receives Fast-Track Designation from US FDA for Marginal Zone Lymphoma
June 29, 2020
Targovax and Oblique enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms
June 25, 2020
Fusion Pharmaceuticals Announces Pricing Of Initial Public Offering